Clinical Trials for Mesothelioma Patients—Sorafenib, Pemetrexed, and Cisplatin: Outcome Measures: Disease Characteristics

Read about the disease characteristics for a current clinical trial about the use of Sorafenib, Pemetrexed, and Cisplatin for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Disease Characteristics Criteria:

·         Histologically or cytologically confirmed non-hematologic malignancy including, but not limited to, any of the following:

• Breast cancer
• Lung cancer
• Colon cancer
• Pancreatic cancer
• Prostate cancer
• Head and neck cancer
• Sarcoma
• No squamous cell histology

·         Advanced disease

o        Must have failed or become intolerant to prior standard therapy and is no longer likely to respond to such therapy

• Patients with mesothelioma do not have to meet prior therapy requirements in order to be enrolled on the study since the combination of cisplatin and pemetrexed disodium is considered current standard first-line therapy for mesothelioma
• Measurable or nonmeasurable disease as defined by RECIST criteria

·         No known brain metastasis

• Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis

·         No clinically significant third-space fluid, such as pleural effusion or ascites

• Third-space fluid allowed provided it can be completely drained

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.